Innovation in microsampling for therapeutic drug monitoring of gentamicin in neonates: a proof-of-concept study (Letter)
File version
Author(s)
Irwin, AD
Hosking, F
August, D
Schoenmaker, B
Pandey, S
Wallis, SC
Lipman, J
Roberts, JA
Davies, MW
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
License
Abstract
Dear Editor, Neonatal sepsis is a significant cause of global mortality and recent studies indicate that the rising incidence of this systemic condition is being driven by the increasing rate of intervention in pre-term neonates [1]. Gram-negative organisms, such as Escherichia coli and Klebsiella pneumoniae, increasingly predominate and are frequently associated with antimicrobial resistance [2].
Journal Title
International Journal of Antimicrobial Agents
Conference Title
Book Title
Edition
Volume
59
Issue
2
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Microbiology
Medical microbiology
Persistent link to this record
Citation
Parker, SL; Irwin, AD; Hosking, F; August, D; Schoenmaker, B; Pandey, S; Wallis, SC; Lipman, J; Roberts, JA; Davies, MW, Innovation in microsampling for therapeutic drug monitoring of gentamicin in neonates: a proof-of-concept study, International Journal of Antimicrobial Agents, 2022, 59 (2), pp. 106513